FDA accepts Otsuka's aripiprazole depot formulation NDA for review bi13280058 Otsuka Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia adults sufficiently complete to permit a substantive review

Cannabis Science Releases Second Cannabis-Extract-Based Formulation Available bi13280058 DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech company developing cannabis products, pleased to announce the successful release of the second Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer ..

New Drug Application for Otsuka's Once-Monthly Aripiprazole Depot Formulation bi13280058 TOKYO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Otsuka Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia adults sufficiently complete to permit a substantive ..

Cannabis Science Prepares Release Of Second Cannabis-Extract-Based Formulatio bi13280058 Cannabis Science, Inc., a pioneering US biotech company developing cannabis products, pleased to announce the preparation to release of the second Cannabis Science brand formulation

TPI to Develop New Formulation for Flagship Product Gingko Mihuan bi13280058 CHENGDU, China, Nov. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Co., Inc. (NYSE Amex: TPI, or the "Company"), a company that specializes patented bio medicine, modernized traditional Chinese medicine (TCM), branded generics and active..

BUSINESS WIRE: OTSUKA PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Histo bi13280058 MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH

FDA accepts Otsuka's aripiprazole depot formulation NDA for review bi13280058 Otsuka Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia adults sufficiently complete to permit a substantive review

Cannabis Science Releases Second Cannabis-Extract-Based Formulation Available bi13280058 DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech company developing cannabis products, pleased to announce the successful release of the second Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer ..

New Drug Application for Otsuka's Once-Monthly Aripiprazole Depot Formulation bi13280058 TOKYO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Otsuka Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia adults sufficiently complete to permit a substantive ..

Cannabis Science Prepares Release Of Second Cannabis-Extract-Based Formulatio bi13280058 Cannabis Science, Inc., a pioneering US biotech company developing cannabis products, pleased to announce the preparation to release of the second Cannabis Science brand formulation

TPI to Develop New Formulation for Flagship Product Gingko Mihuan bi13280058 CHENGDU, China, Nov. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Co., Inc. (NYSE Amex: TPI, or the "Company"), a company that specializes patented bio medicine, modernized traditional Chinese medicine (TCM), branded generics and active..

BUSINESS WIRE: OTSUKA PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Histo bi13280058 MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH

MedinCell Highlights Controlled-Release Strategy as Patent Cliff Bridge at Wi bi13280058 MONTPELLIER, FRANCE and SAN DIEGO, CA-- - MedinCell be meeting decision makers at the Windhover Therapeutic Area Conference Boston to discuss controlled-release strategies for ..

Tapeware Backup Software - Home